



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. SERIAL NO. : 10/729,704  
APPLICANTS : Guenzler-Pukall, et al.  
FILING DATE : 4 December 2003  
GROUP ART UNIT : 1654  
EXAMINER : Roy R. Teller  
DOCKET NO. : FP0602.1 US  
TITLE : TREATMENT OF DIABETES

Commissioner for Patents  
PO Box 1450  
Alexandria VA 22313-1450

**TRANSMITTAL**

The following items accompany this Transmittal:

1. Return Receipt Postcard
2. Information Disclosure Statement (2pgs)
3. PTO/SB/08a (1pg)
4. PTO/SB/08b (1pg)
5. Two (2) References (*Almansa* (1993) 2121-2138, *Finch* (1980) 1405-1410)
6. Copy of Partial European Search Report (6pgs)

**Applicant claims small entity status under 37 C.F.R. 1.27.**

The Commissioner is hereby authorized to charge any fees necessary in this communication to Deposit Account No. 50-0811, referencing Docket No. FP0602.1 US.

Please call Applicant's representative at 415-978-1748 with any questions regarding this communication or the above-identified application.

Respectfully submitted,

Date: 3-11-2011

By:

Paul Borchardt  
Paul Borchardt, Ph.D.  
Reg. No. 53,999

FibroGen, Inc.  
409 Illinois Street  
San Francisco, CA 94158  
Main: 415-978-1200  
Direct: 415-978-1748  
Facsimile: 415-978-1917  
[pborchardt@fibrogen.com](mailto:pborchardt@fibrogen.com)

**Certificate of mailing or transmission under 37 CFR § 1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 11 March 2011.

Name: Michael Moores

Signature: [Signature]